Entera Bio Ltd. Ordinary Shares (ENTX) Stock
Key stats
- Market cap
- $560.72M
- Price / Earnings ratio
- -19.2x
- EPS (TTM)
- -$0.39
- Volume
- Loading
- 52-week high
- $4.20
- 52-week low
- $0.91
Source: third-party data provider, as of November 13, 2026
Compare with ENTX
Recent news

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
ENTX

Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
ENTX

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
ENTX

ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead
ENTX
Technical indicators
- RSI 14
- 60.11
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.09
- MACD histogram
- 0.02
- SMA 50
- $2.89
- Price above SMA 50
- EMA 50
- $2.90
- Price above EMA 50
- SMA 200
- $1.97
- Price above SMA 200
- EMA 200
- $2.21
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement
ENTX

Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
ENTX

ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally?
ENTX

ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead
ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead
ENTX

3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
ENTX

3 Meme Stocks to Buy on the Dip: June 2024
3 Meme Stocks to Buy on the Dip: June 2024
ENTX

3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024
3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024
ENTX

New Strong Buy Stocks for November 21st
New Strong Buy Stocks for November 21st
ENTX

New Strong Buy Stocks for November 16th
New Strong Buy Stocks for November 16th
ENTX

Recession Fears are Creating a Golden Opportunity for Biotech Stocks
Recession Fears are Creating a Golden Opportunity for Biotech Stocks
ENTX
About Entera Bio Ltd. Ordinary Shares
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Miranda J. Toledano M.B.A. | CEO & Director | 1977 |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer | 1978 |
| Ms. Dana Yaacov-Garbeli CPA | Chief Financial Officer | 1983 |
| Dr. Gregory Burshtein Ph.D. | Chief of Research & Development | 1977 |
| Dr. Rachel B. Wagman | Chief Clinical Advisor | — |
| Ms. Cherin Smith | Executive VP & Head of Clinical Operations | — |
| Dr. Constantin Itin Ph.D., R.Ph. | Head of Biopharmaceutics & Bioanalytics | — |
| Ms. Michele McDermott | MD & EVP of Medical Affairs | — |
| Mr. Riccardo Paolo Camisasca M.D. | Chief Medical Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 60.11
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.09
- MACD histogram
- 0.02
- SMA 50
- $2.89
- Price above SMA 50
- EMA 50
- $2.90
- Price above EMA 50
- SMA 200
- $1.97
- Price above SMA 200
- EMA 200
- $2.21
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $9.00
- Average
- $10.00
- High
- $11.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +47.3 | -0.3 | +0.3 | +10.7 | +4.2 |



